Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome.
The incidence of myelodysplastic syndromes increases with age and a high prevalence of co-morbid conditions has been reported in these patients. So far, risk assessment in myelodysplastic syndromes has been mainly based on disease status. We studied the prognostic impact of comorbidity on the natural history of myelodysplastic syndrome with the aim of developing novel tools for risk assessment. The study population included a learning cohort of 840 patients diagnosed with myelodysplastic syndrome in Pavia, Italy, and a validation cohort of 504 patients followed in Duesseldorf, Germany. Information on comorbidity was extracted from detailed review of the patients' medical charts and laboratory values at diagnosis and during the course of the disease. Univariable and multivariable survival analyses with both fixed and time-dependent covariates were performed using Cox's proportional hazards regression models. Comorbidity was present in 54% of patients in the learning cohort. Cardiac disease was the most frequent comorbidity and the main cause of non-leukemic death. In multivariable analysis, comorbidity had a significant impact on both non-leukemic death (P=0.01) and overall survival (P=0.02). Cardiac, liver, renal, pulmonary disease and solid tumors were found to independently affect the risk of non-leukemic death. A time-dependent myelodysplastic syndrome-specific comorbidity index (MDS-CI) was developed for predicting the effect of comorbidity on outcome. This identified three groups of patients which showed significantly different probabilities of non-leukemic death (P<0.001) and survival (P=0.005) also in the validation cohort. Landmark survival analyses at fixed time points from diagnosis showed that the MDS-CI can better define the life expectancy of patients with myelodysplastic syndrome stratified according to the WHO-classification based Prognostic Scoring System (WPSS).Comorbidities have a significant impact on the outcome of patients with myelodysplastic syndrome. Accounting for both disease status by means of the WPSS and comorbidity through the MDS-CI considerably improves risk stratification in myelodysplastic syndromes.
Department of Hematology Oncology, University of Pavia Medical School & Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy.
Matteo G
MG
Della Porta
Luca
L
Malcovati
Corinna
C
Strupp
Ilaria
I
Ambaglio
Andrea
A
Kuendgen
Esther
E
Zipperer
Erica
E
Travaglino
Rosangela
R
Invernizzi
Cristiana
C
Pascutto
Mario
M
Lazzarino
Ulrich
U
Germing
Mario
M
Cazzola
D000293:Adolescent; D000328:Adult; D000368:Aged; D015897:Comorbidity; D005260:Female; D005858:Germany; D006331:Heart Diseases / Q000453:epidemiology / Q000473:pathology; D006801:Humans; D007558:Italy; D007674:Kidney Diseases / Q000453:epidemiology / Q000473:pathology; D008107:Liver Diseases / Q000453:epidemiology / Q000473:pathology; D008171:Lung Diseases / Q000453:epidemiology / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000175:diagnosis / Q000453:epidemiology* / Q000473:pathology; D009369:Neoplasms; D011379:Prognosis; D018570:Risk Assessment / Q000145:classification; D012720:Severity of Illness Index; D016019:Survival Analysis